~~<i id='846D2E4115'><strike id='846D2E4115'><tt id='846D2E4115'><pre id='846D2E4115'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

explore

author：hotspot 2025-09-30 00:37:05 - browse：35573

translucent 3D DNA helix with blue and purple background — Adobe

Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease.

The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November. Verve now intends to recruit participants from U.S. sites into a Phase 1 study that’s been underway since last year in New Zealand and the United Kingdom.

“We’re thrilled to get this clearance for VERVE-101,” said Verve CEO Sek Kathiresan. “Our study is called HEART-1 and our plan now is to activate U.S. sites.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Cosmetics set for new safety regulation. Why the industry is on board

focus

knowledge

explore

focus

leisure time

focus

AlexBrandon/APThefederalgovernmentissuingtoblockaproposedhospitaldealinNorthCarolina,allegingitwould

WSS

10 reasons why health care startups fail

Why hospitals are withdrawing from US News rankings

Medicare has a new plan to address drug shortages

Bernie Sanders is gearing up to subpoena pharma CEOs

Biden tests positive for Covid

Biogen walks away from Aduhelm, years after polarizing approval

hotspot

explore

focus

Novavax promises a turnaround & Lilly roils the obesity market

Medicare drug price negotiation legal challenge met with skepticism

Activists slam private health insurers over coverage restrictions

Medicare to cover more brain scans for Alzheimer’s patients

In Memoriam: Notable people who died in 2023

STAT Virtual Event: The State of Biosimilars: What to Watch

What does generative AI mean for health care? We asked experts

Boston competes with Raleigh

Bright Health sells Medicare Advantage business to Molina

Custom gene therapy hints at new path for rare disease treatments

knowledge

Reconstructing family trees of blood cells may help predict disease

Venture capital firm's plans to take over Akron hospital face hurdles

Why you shouldn’t ask, “What country has the best health care?”

Boston competes with Raleigh

Health Care Service Corp to buy Cigna Medicare Advantage plans

Sanders adds drug shortage policies to pandemic preparedness bill

explore

focus

leisure time

focus